Please login to the form below

Not currently logged in
Email:
Password:

Catabasis hires Rick Modi as its chief business officer

Will help the firm develop its flagship Duchenne muscular dystrophy product

The US biotech firm Catabasis Pharmaceuticals has named Rick Modi as its new chief business officer. 

Modi brings to Catabasis 15 years of experience in corporate, business and product commercialisation strategy.

Jill Milne, co-founder and chief executive of Catabasis, said: “Rick has valuable experience across multiple brands, including orphan drug positioning, commercialisation and marketing. 

“We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”

Modi added: “Catabasis has a novel approach to drug development that allows for simultaneous modulation of multiple targets in a disease pathway, and I am privileged to join this team as we seek to bring disease-modifying treatments to patients with DMD or severe lipid disorders."

Prior to joining Catabasis, Modi was senior vice president, global marketing at InterMune - an orphan drug company that was acquired by Roche late last year.

He played a large role in the launch of InterMune's flagship product, the lung-scarring drug Esbriet (pirfenidone)

Modi has also held roles of increasing responsibilities in corporate strategy, new product planning and sales and marketing at AstraZeneca's biologics arm MedImmune as well as J&J's subsidiary Centocor.

16th February 2015

From: Research, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics